Levetiracetam Tablet, Film Coated
Product Images NDC 72865-187

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72865-187). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000-mg (1000 mg)

Levetiracetam Tablets, USP 1000 mg film-coated oral tablets packaging label by XLCare Pharmaceuticals Inc. The label states the product contains 60 tablets and is prescription only (Rx only). It includes storage instructions, pharmacist dispensing advisories, and contact information for the manufacturer and medication guides website.*

FDA Label Image

250-mg (250 mg)

Levetiracetam Tablets, USP 250 mg film-coated tablets packaging label from XLCare Pharmaceuticals Inc. The label includes NDC 72865-187-12 and indicates a package size of 120 tablets. It features pharmacist instructions, storage conditions, and contact information for the manufacturer and distributor.*

FDA Label Image

500-mg (500 mg)

This is a packaging label for Levetiracetam Tablets, USP 500 mg film-coated tablets. The label shows the product name, strength, and quantity of 120 tablets. It is labeled as Rx only and manufactured by XLCare Pharmaceuticals Inc. Additional dispensing instructions, storage conditions, and contact information are also included.*

FDA Label Image

750-mg (750 mg)

Label for Levetiracetam Tablets, USP 750 mg by XLCare Pharmaceuticals Inc. The film-coated oral tablets come in a bottle of 120 count. The label includes pharmacist instructions and storage conditions. It also shows the NDC 72865-189-12 and manufacturer details, including Annora Pharma Pvt. Ltd. in India.*

FDA Label Image

Fig-1 (Fig 1)

A bar chart comparing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The vertical axis shows percentage of patients from 0% to 45%, and the chart highlights higher patient percentages for both Levetiracetam doses compared to placebo.*

FDA Label Image

Fig-2 (Fig 2)

A vertical bar chart comparing the percentage of patients in three groups: Placebo (N=111) at 6.3%, Levetiracetam 1000 mg/day (N=106) at 20.8%, and Levetiracetam 2000 mg/day (N=105) at 35.2%. The y-axis shows the percentage of patients ranging from 0% to 45%. Each of the Levetiracetam groups displays a statistically significant increase as indicated by asterisks above the bars.*

FDA Label Image

Fig-3 (Fig 3)

A bar chart comparing the percentage of patients for two groups: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The y-axis shows the percentage of patients ranging from 0% to 45%. The Placebo group has about 14.4%, while the Levetiracetam group shows approximately 39.4%, indicating a higher patient percentage in the Levetiracetam treatment group.*

FDA Label Image

Fig-4 (Fig 4)

A bar chart comparing the percentage of patients in two groups: Placebo (N=97) and Levetiracetam (N=101). The chart shows 19.6% of patients in the placebo group and 44.6% in the Levetiracetam group, with the vertical axis labeled as % of Patients.*

FDA Label Image

Fig-5 (Fig 5)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis represents the percentage of patients from 0% to 45%. The placebo group (N=51) shows 19.6%, and the Levetiracetam group (N=58) shows 43.1%, with an asterisk above the Levetiracetam bar indicating statistical significance.*

FDA Label Image

Fig-6 (Fig 6)

A bar chart comparing the percentage of patients in two groups: Placebo (N=84) with 45.2% and Levetiracetam (N=79) with 72.2%. The y-axis represents the percentage of patients from 0% to 100%, illustrating a higher percentage in the Levetiracetam group.*

FDA Label Image

Levestructure (Levestructure)

Chemical structure of Levetiracetam, showing its molecular arrangement including a pyrrolidone ring and associated functional groups consistent with the active ingredient Levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.